Generation Bio Co

GBIO

Company Profile

  • Business description

    Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

  • Contact

    301 Binney Street
    CambridgeMA02142
    USA

    T: +1 617 655-7500

    https://www.generationbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    115

Stocks News & Analysis

stocks

The long-term case for compounders

Compounders tend to deliver steadier, more durable profit growth across full cycles, making them better suited for long-term investors.
stocks

Record production for Woodside

Our fair value is updated as progress is made on new development projects.
stocks

Meta earnings: Strong end to 2025 as AI monetization begins to show

Investors please with latest results.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,100.5010.50-0.12%
CAC 408,126.5355.170.68%
DAX 4024,538.81229.350.94%
Dow JONES (US)48,892.47179.09-0.36%
FTSE 10010,223.5451.780.51%
HKSE27,387.11580.98-2.08%
NASDAQ23,461.82223.30-0.94%
Nikkei 22553,956.50633.651.19%
NZX 50 Index13,424.781.600.01%
S&P 5006,939.0329.98-0.43%
S&P/ASX 2008,808.4012.70-0.14%
SSE Composite Index4,117.950.000.00%

Market Movers